Genes, 13 (5), 730
11 Clinical Pearls Patients should be counselled on the potential effects of their systemic medications on their ocular health and vision GLP-1 receptor agonists may serve an adjunct role in helping patients with IIH achieve optimal weight and guard against visual loss The current ophthalmic literature is varied with regard to GLP-1 receptor agonists and risk of NA-AION, and clinicians must stay informed as data continues to emerge on this topic References Mitchell JL, Lyons HS, Walker JK, et al
Understanding proper storage requirements is essential for patients using semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro), and other GLP-1 formulations to ensure optimal therapeutic outcomes and medication safety
The program is expected to run through December 31, 2027, and is designed to expand access to certain FDA-approved weight loss medications while CMS evaluates long-term coverage options
Strain Diversity and Potency For probiotics, look for a "CFU" (Colony Forming Unit) count that is backed by science, but do not focus on the highest number alone
